Literature DB >> 9562106

How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis.

D A Mitchison1.   

Abstract

OBJECTIVE: To explore mechanisms by which drug resistance might arise as a result of poor compliance during short course chemotherapy.
DESIGN: Four theoretical mechanisms are first described.
RESULTS: Examples of the way the mechanisms probably operate are taken from: 1) a study of once-weekly chemotherapy with streptomycin and isoniazid, and 2) the pattern of drug susceptibility in cultures from patients who relapsed after the end of treatment.
CONCLUSION: Good compliance is vitally important. The value of a fourth drug in the initial phase of chemotherapy in preventing resistance is questioned. An explanation for mono-resistance to rifampicin in patients with the acquired immune deficiency syndrome (AIDS) is suggested.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9562106

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  96 in total

Review 1.  Tuberculosis: 9. Treatment.

Authors:  E Hershfield
Journal:  CMAJ       Date:  1999-08-24       Impact factor: 8.262

Review 2.  Drug-resistant tuberculosis.

Authors:  R Long
Journal:  CMAJ       Date:  2000-08-22       Impact factor: 8.262

3.  Prediction of resistance development against drug combinations by collateral responses to component drugs.

Authors:  Christian Munck; Heidi K Gumpert; Annika I Nilsson Wallin; Harris H Wang; Morten O A Sommer
Journal:  Sci Transl Med       Date:  2014-11-12       Impact factor: 17.956

4.  Predictors of treatment failure among pulmonary tuberculosis patients in Mulago hospital, Uganda.

Authors:  E Namukwaya; F N Nakwagala; F Mulekya; H Mayanja-Kizza; R Mugerwa
Journal:  Afr Health Sci       Date:  2011-08       Impact factor: 0.927

5.  Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment.

Authors:  Geraint R Davies; Richard Brindle; Saye H Khoo; Leon J Aarons
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 6.  Novel approaches to developing new antibiotics for bacterial infections.

Authors:  A R M Coates; Y Hu
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

Review 7.  Heterogeneity in tuberculosis.

Authors:  Anthony M Cadena; Sarah M Fortune; JoAnne L Flynn
Journal:  Nat Rev Immunol       Date:  2017-07-24       Impact factor: 53.106

8.  High risk and rapid appearance of multidrug resistance during tuberculosis treatment in Moldova.

Authors:  Helen E Jenkins; Valeriu Crudu; Viorel Soltan; Ana Ciobanu; Liliana Domente; Ted Cohen
Journal:  Eur Respir J       Date:  2014-02-20       Impact factor: 16.671

9.  Antituberculosis drug resistance acquired during treatment: an analysis of cases reported in California, 1994-2006.

Authors:  Travis C Porco; Peter Oh; Jennifer M Flood
Journal:  Clin Infect Dis       Date:  2012-12-07       Impact factor: 9.079

10.  Epidemic levels of drug resistant tuberculosis (MDR and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South Africa.

Authors:  Helen S Cox; Cheryl McDermid; Virginia Azevedo; Odelia Muller; David Coetzee; John Simpson; Marinus Barnard; Gerrit Coetzee; Gilles van Cutsem; Eric Goemaere
Journal:  PLoS One       Date:  2010-11-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.